clinical trial · NCT07566195
Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations
Chronic Obstructive Pulmonary DiseaseCOPDTozorakimab Dose Regimen 1Tozorakimab Dose Regimen 2
brief summary
ROMEO is a Phase III, multicentre, open-label, chronic-dosing extension study evaluating the long-term safety of two dose regimens of tozorakimab in participants with COPD and a history of exacerbations. Eligible participants must have completed one of the predecessor studies.
started
May 5, 2026
primary completion
Dec 29, 2028
completion
Dec 29, 2028
last updated
Jun 10, 2026
official title
A Phase III, Multicentre, Open-Label, Chronic Dosing, Extension Study to Evaluate the Long-term Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (ROMEO)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol